UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2024
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. |
| Description |
| | |
Exhibit 99.1 | | Announcement relating to total voting rights |
| | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HUTCHMED (CHINA) LIMITED | |
| | |
| | |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |
Date: May 31, 2024
3
Exhibit 99.1
Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Friday, May 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at May 31, 2024, the issued share capital of HUTCHMED consisted of 871,264,820 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.
The above figure of 871,264,820 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
For illustrative purposes only, the 871,264,820 ordinary shares would be equivalent to 871,264,820 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 174,252,964 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. Іt is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Іt has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also marketed in the U.S. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Contacts
Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
Media Enquiries | |
Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com |
Zhou Yi, Brunswick | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
Nominated Advisor | |
Atholl Tweedie / Freddy Crossley / Daphne Zhang, Panmure Gordon | +44 (20) 7886 2500 |
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